AIM: To determine the prevalence of hepatitis B virus (HBV) genotypes in Iranian hepatitis B surface antigen (HBsAg) carriers, chronic hepatitis B and cirrhotic patients. METHODS: A total of 109 HBsAg-positive patients were included in this study. HBV genotypes were determined by using INNO-LiPA methodology which is based on the reverse hybridization principle. RESULTS: The distribution of patients with different stages of liver disease was as follows: 95(86.4%) chronic hepatitis, 11(10%) liver cirrhosis, and 3(2.7%) inactive carrier. Of the chronic hepatitis and liver cirrhosis patients, 26.4% were HBeAg-positive while 70% were HBeAg-negative. Genotype D was the only detected type found in all patients. CONCLUSION: Classifying HBV into genotypes has to be cost-effective and clinically relevant. Our study indicates that HBV genotype D prevails in the Mediterranean area, Near and Middle East, and South Asia. Continued efforts for understanding HBV genotype through international co-operation will reveal further virological differences of the genotypes and their clinical relevance.
AIM: To determine the prevalence of hepatitis B virus (HBV) genotypes in Iranian hepatitis B surface antigen (HBsAg) carriers, chronic hepatitis B and cirrhotic patients. METHODS: A total of 109 HBsAg-positive patients were included in this study. HBV genotypes were determined by using INNO-LiPA methodology which is based on the reverse hybridization principle. RESULTS: The distribution of patients with different stages of liver disease was as follows: 95(86.4%) chronic hepatitis, 11(10%) liver cirrhosis, and 3(2.7%) inactive carrier. Of the chronic hepatitis and liver cirrhosispatients, 26.4% were HBeAg-positive while 70% were HBeAg-negative. Genotype D was the only detected type found in all patients. CONCLUSION: Classifying HBV into genotypes has to be cost-effective and clinically relevant. Our study indicates that HBV genotype D prevails in the Mediterranean area, Near and Middle East, and South Asia. Continued efforts for understanding HBV genotype through international co-operation will reveal further virological differences of the genotypes and their clinical relevance.
Authors: E Orito; T Ichida; H Sakugawa; M Sata; N Horiike; K Hino; K Okita; T Okanoue; S Iino; E Tanaka; K Suzuki; H Watanabe; S Hige; M Mizokami Journal: Hepatology Date: 2001-09 Impact factor: 17.425
Authors: Peyman Adibi; Rezvan Ghassemian; Seyed-Moayed Alavian; Mitra Ranjbar; Amir H Mohammadalizadeh; Fariborz Nematizadeh; Mojgan Mamani; Mahdi Rezazadeh; Fariba Keramat; Ali Ardalan; Abbas Esmaeili; Mohammad R Zali Journal: Saudi Med J Date: 2004-10 Impact factor: 1.484
Authors: K Yalcin; H Degertekin; I H Bahcecioglu; A Demir; M Aladag; B Yildirim; S Horasanli; S Ciftci; S Badur Journal: Infection Date: 2004-02 Impact factor: 3.553
Authors: V A Mbayed; J L López; P F Telenta; G Palacios; I Badía; A Ferro; C Galoppo; R Campos Journal: J Clin Microbiol Date: 1998-11 Impact factor: 5.948
Authors: Mojtaba Oraki Kohshour; Hamid Galehdari; Ali Mohammad Foroughmand; Behnaz Andashti; Mohammad Ali Jalalifar; Ali Bidmeshkipour Journal: Hepat Mon Date: 2010-06-01 Impact factor: 0.660